Regeneron Reveals $177M Equity Portfolio, Headlined by $114M Parabilis Medicines Stake
REGN sits 45% above its 52-week low of $541.
Summary
Regeneron's 13F filing reveals a $177.2 million public equity portfolio, headlined by a $114.0 million stake in Parabilis Medicines, a recent strategic partner. The disclosure provides the first look at the size of Regeneron's investment following their May 2026 collaboration.
Key Events · Ownership and Investor Activity · REGN
-
$114M Parabilis Medicines Stake
Regeneron holds 4,166,666 shares of Parabilis Medicines valued at $114.0 million, representing the largest position in its $177.2 million public equity portfolio.
-
Strategic Collaboration Context
The Parabilis stake follows a May 2026 research partnership that included a $75 million equity investment, indicating Regeneron has increased its ownership beyond the initial deal terms.
-
$62.7M Intellia Therapeutics Position
Regeneron also disclosed a $62.7 million stake in Intellia Therapeutics (3,702,995 shares), a gene-editing company, signaling interest in next-generation therapeutic platforms.
-
Portfolio Snapshot as of June 30, 2026
The 13F filing provides the first public look at Regeneron's equity holdings, with a total reported value of $177.2 million across three positions.
Analysis · REGN · Life Sciences
A 13F filing from Regeneron unveils a $177.2 million public equity portfolio as of June 30, 2026. The largest holding is a $114.0 million position in Parabilis Medicines (4.17 million shares), a company with which Regeneron recently launched a strategic collaboration. This investment builds on the partnership announced in May 2026, which included a $75 million equity component, suggesting Regeneron has taken a significant ownership stake beyond the initial deal terms. The portfolio also features a $62.7 million stake in Intellia Therapeutics, a gene-editing firm, and a small position in Adicet Bio. For a company of Regeneron's size, these holdings are modest but signal strategic intent in cell and gene therapy. The Parabilis stake, in particular, underscores Regeneron's commitment to the collaboration and could be viewed as a vote of confidence in the partnership's potential.
At the time of this filing, REGN was trading at $784.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.8B. The 52-week trading range was $541.00 to $821.11. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.